According to the National Comprehensive Cancer Network Guidelines for NSCLC (version 4.2020), it is recommended that all patients with advanced non-squamous NSCLC undergo testing for crucial driver genes, including EGFR, ALK, BRAF, and ROS1, regardless of clinical variables [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.